About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 ...

Selected as a C-Further program with up to $1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...

Restoring the gut microbiota through fecal microbiota transplantation reversed these effects. The treatment replenished CX3CR1-positive NK cells, reduced lung damage, and improved survival. Targeted ...

Investing.com -- MiNK Therapeutics (NASDAQ:INKT) shares surged 80% Tuesday following the announcement of a collaboration with C-Further to develop a PRAME-targeted iNKT cell therapy for pediatric ...

MiNK Therapeutics (NASDAQ:INKT) shares climbed about 80% on Tuesday after the company revealed a collaboration with C-Further aimed at developing a PRAME-targeted iNKT cell therapy for pediatric ...

Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial reven ...

Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancers Mechanisms of action support enhanced activity of GSK-3ß plus ...

Why do diabetic wounds refuse to heal? A new scientific review highlights how disruptions in the timing and behavior of ...

Proof-of-concept trial in a single patient shows that cells can survive transplantation without immunosuppression ...

Dr. Todd Maderis, ND  Exploring immune dysregulation, viral reactivation, mitochondrial impairment, and treatment implications in post-EBV fatigue syndromes ...

Sepsis and severe pneumonia are frequently accompanied by disruption of the gut microbiota, leading to immune dysfunction and ...